Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for CRTC1-MAML2 Fusion and CREB Pathway Target Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CRTC1/TORC1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CRTC1 Recombinant Protein (Full-length & CREB-binding domain) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for PPI screening. |
View CRTC1 Products |
| Gene Delivery | CRTC1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and nuclear translocation assays. |
View CRTC1 Products |
| Benchmark Ab | Anti-CRTC1 Recombinant Antibody Validated for Western Blot and Immunofluorescence control assays. |
View CRTC1 Products |
| Validator | CRTC1 siRNA Set For knockdown verification and target validation in cancer cell lines. |
View CRTC1 Products |
| Related Target A | CREB1 Direct binding partner of CRTC1; essential for establishing transcription factor PPI assays. |
View CREB1 Products |
| Related Target B | MAML2 Key fusion partner (CRTC1-MAML2) in mucoepidermoid carcinoma; critical for oncogenic pathway research. |
View MAML2 Products |
| Related Target C | SIK1 (Salt-Inducible Kinase 1) Upstream kinase regulating CRTC1 phosphorylation and nuclear translocation. |
View SIK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) Assay Sensitivity | High-purity recombinant CRTC1 and CREB1 proteins with precise tag options (GST/His) for robust TR-FRET assays. |
| CRTC Family Off-target Profiling | Homolog panels (CRTC2, CRTC3) strictly verified by mass spectrometry to ensure candidate selectivity. |
| Nuclear Translocation Tracking | Lentiviral vectors expressing GFP-tagged CRTC1 for high-content screening of translocation inhibitors. |
| Specificity Validation | Sequence-verified siRNA pool included to confirm target-specific gene knockdown and phenotypic rescue. |
Live CRTC1/TORC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CRTC1/TORC1 therapeutics is intensifying, with major players shifting focus from traditional systemic chemotherapy to targeted transcription factor complex disruptors and upstream kinase modulators. As first-generation SIK inhibitors and protein-protein interaction (PPI) disruptors reach preclinical validation, the next wave of R&D is targeting the specific CRTC1-MAML2 fusion oncogene in mucoepidermoid carcinoma (MEC) and other fusion-positive solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic Institutions, Biotech Startups | Mucoepidermoid Carcinoma, Lung Cancer | CRTC1-CREB1 binding disruption assay (Requires highly pure, active recombinant domains) |
| SIK Inhibitors (Upstream Modulators) | Deciphera Pharmaceuticals, Bristol Myers Squibb | Oncology, Autoimmune Diseases | Phosphorylation-dependent translocation assays (Requires Lentivirus for stable cell line construction) |
| Targeted Protein Degraders (PROTACs) | Targeted Degradation Biotechs | CRTC1-MAML2 Fusion-positive Cancers | Ubiquitination and degradation validation (Requires sequence-verified CRTC1 proteins and antibodies) |